Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate vs Raloxifene after Denosumab in Postmenopausal Osteoporosis
NCT03623633Phase 4Unknown
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2018
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of alendronate, raloxifene in postmenopausal osteoporosis, sponsored by Massachusetts General Hospital. Status: unknown.
02
Drugs
alendronateraloxifene
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT03623633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623633.